KBI Biopharma, Inc. Secures Swissmedic Regulatory Establishment License for State-of-the-Art Mammalian Cell Manufacturing Facility in Geneva
GENEVA, December 20, 2022– KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced its recently expanded, state-of-the-art Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory establishment license. This important designation demonstrates compliance with current Good Manufacturing Practice (cGMP) standards for the production and release of drug substances for clients.
The license allows KBI to fully support clients in their next phases of growth and certifies KBI's manufacturing capabilities in a cGMP environment.
"It's critical for our drug development clients moving into phase one and phase two clinical trials to confidently partner with trusted cGMP-certified manufacturers for their growth and future success," said Mike Landau, Chief Operating Officer of KBI and Selexis. "This license is a critical component of KBI's streamlined and cost-effective solutions to help worldwide biotechnology companies optimize their processes and advance their innovative therapies."
This milestone comes only five months after a significant facility expansion in July 2022, when KBI and Selexis announced the operation of the fully integrated, 8,733 square-meter site combining the Selexis Cell Line Development services (CLD) and KBI's contract development and manufacturing services. The facility, providing clients with true end-to-end CLD, process/analytical development, and manufacturing, continues to generate jobs in the region.
Building on KBI's strong commitment to quality, the timing of the Swissmedic license approval coincided with the company's Leuven, Belgium facility for analytical services, successfully completing a second inspection that resulted in its cGMP renewal.
KBI Biopharma, Inc., a JSR Life Sciences company, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
Contact details
-
- Aruna Mor
-
KBI Biopharma Company Inquiries
VP, Business Strategy & Marketing - amor@kbibiopharma.com
- +1 442-357-0123
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
Tim Lowery Appointed Interim CEO of KBI and Selexis
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.
KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva,...
KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.
Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispeci...
Selexis and KBI announced today that they have signed service agreements with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting canc...